Asset Publisher

Back Part 1: Establishing direct-to and from-patient clinical trial supply chains

Critically ill patients increasingly can participate in life-saving and life-changing cell & gene therapy clinical trials without having to leave their homes with the direct-to-patient and direct-from-patient model. So how do you set up these supply chains? How do you mitigate risk? And how do you ensure they’re resilient? Mike Sweeney, QuickSTAT’s Global Head of Strategy for CGT and DTP products, explains.

Few aspects of our lives and routines changed more significantly over the last several years, or more rapidly and permanently than supply chains. Post-COVID, much of life returned to normal, but one important area of supply chains found a new normal, in semi-miraculous ways and very much for the better. These are direct-to-patient and direct-from-patient clinical trial supply chains. Known as DTP or DFP, these supply chains have become essential lifelines. But with this clinical trial model comes new challenges around time, temperature and logistics.

So how do you set up these supply chains? How do you mitigate risk? And how do you ensure they're resilient?

Mike Sweeney, QuickSTAT's Global Head of Strategy for CGT and DTP products, explains how to safely transport life-saving and life-changing shipments no matter where in the world the patient may be.

Download transcript